Factors Associated with Sustained Remission among Chronic Opioid Users

Ramin Shiraly MD¹, Maryam Taghva MD²

Abstract

Background: Chronic opioid use is a major public health problem with significant morbidity. The aim of this study was to investigate factors associated with sustained remission among a sample of Iranian chronic opioid users in Shiraz, Iran.

Methods: This was a cross-sectional study to evaluate sustained remission among chronic opiate users aged 20-60 years. Participants included two groups: 365 people who have been in sustained remission for the past year, and 187 persons who did not achieve remission for the past one year. Then, demographic and factors related to drug use pattern and previous treatments were compared between two groups. Pearson chi-square test was used for univariate analysis and backward stepwise logistic regression was used to estimate adjusted odds ratios (AORs).

Findings: Our findings showed that sustained remission was associated with Narcotic Anonymous (NA) participation [AOR = 3.28, 95% confidence interval (CI): 2.19-4.89, P < 0.001], male gender (AOR = 2.53, 95% CI: 1.45-4.43, P = 0.001), younger age of onset (AOR = 1.63, 95% CI: 1.03-2.58, P = 0.037), higher total years of opioid use (AOR = 2.13, 95% CI: 1.42-3.19, P < 0.001), no history of imprisonment (AOR = 2.11, 95% CI: 1.16-3.85, P = 0.015), and family support (AOR = 2.58, 95% CI: 1.33-5.01, P = 0.005).

Conclusion: Participation in self-help groups can be a suitable alternative in predicting sustained remission among chronic opiate users. Chronic opioid users should be encouraged by the physicians who are involved in the treatment of drug addiction to participate in NA programs.

Keywords: Drug addiction; Opioids; Substance use disorders; Opiate substitution treatment

Citation: Shiraly R, Taghva M. Factors Associated with Sustained Remission among Chronic Opioid Users. Addict Health 2018; 10(2): 86-94.

Received: 27.12.2017

Accepted: 28.02.2018

¹- Assistant Professor, Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
²- Resident, Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Correspondence to: Ramin Shiraly MD, Email: shiralyr@sums.ac.ir
Introduction

Chronic opioid use is a major public health problem with significant morbidity that affects more than 21 million people worldwide.\(^1,2\) The natural course of chronic opioid use includes opioid dependency, repeated attempts to stop substance use, and frequent relapse.\(^3\)

Opioids are the most commonly used drugs in Iran with the highest rate of opiate use in the world.\(^4,5\) In addition to opium, which is traditionally the main drug of abuse in Iran, there has been an increase in the use of heroin among Iranian opiate users within the last decades,\(^6,7\) and more than 80% of drug abuse treatment cases were related to opiate addicts who were seeking treatment.\(^4\)

Abrupt cessation of opioids without any treatment is less likely and a substantial number of chronic addicts resort to therapeutic modalities. Findings from prospective studies indicate that participation in formal and prolonged treatment is generally associated with better outcomes.\(^8,9\) A variety of treatment methods are used by chronic opioid users to control their addiction, often with a multiple stop-and-start pattern.\(^10\) Harm reduction and abstinence-oriented policies are the two strategies to control opioid use disorder (OUD). Many opioid addicts experience single or combined treatment methods to overcome their addiction; hence, the efficacy of a single method cannot be measured accurately.\(^8\)

The most common pharmacological methods for treatment of opioid addiction are detoxification and maintenance therapy with drugs such as opioid agonists and antagonists, and alpha-2-adrenergic agonists. Agonist maintenance therapy is one of the most common types of treatment because of the better outcomes attained in comparison with other drug therapies.\(^11\) Moreover, participation in 12-step or Narcotic Anonymous (NA) groups is another common method used by opioid addicts to control opioid use.\(^12\)

Although drug addiction is defined as a chronic relapsing disease, which has periods of exacerbation and remission,\(^13,14\) duration of remissions is an important factor for predicting future physical and mental health of patients. The longer the periods of remission, the better would be the physical, psychological, and social function and ultimate prognosis.\(^15\)

Factors associated with remission from alcohol dependence have been extensively studied, but few studies have investigated factors associated with sustained remission from other substances including opiates.\(^16,17\) Follow up of patients after outpatient treatment programs indicates that better outcomes are associated with older age, lower severity of addiction, less psychiatric comorbidity, longer duration of treatments, and participation in 12-step programs.\(^18,19\) In addition, gender, race/ethnicity, educational attainment, income, marital status, comorbid substance use disorders (SUDs), and drug treatment utilization have been associated with sustained remission.\(^20,21\)

In the present study, we compared two groups of opiate addicts: chronic opioid users who maintained remission and those who did not achieve remission for the past one year.

Methods

This cross-sectional study with a control group was carried out between June to August 2017 in Shiraz, Iran. Study population included people aged 20-60 years with a history of at least two years of continuous use of opium or heroin, and involvement in at least one formal treatment program to stop their addiction. All of the participants stated opium or heroin as their primary drug of choice. Pure users of cannabis, methamphetamine, and prescription opioids such as tramadol or methadone were excluded from the study. According to The Diagnostic and Statistical Manual of Mental Disorders-\(^5\)th Edition (DSM-5) criteria for SUDs, sustained remission is defined as ≥ 12 months without meeting SUD criteria, except craving.\(^22\) Considering the cross-sectional design of this study, we considered sustained remission as not meeting the DSM-5 criteria at the time of the study and no self-reported relapse during the last year. We used outpatient clinics and self-help groups sessions as settings to access chronic opioid users who were seeking treatment modalities. The sample size was calculated by assuming alpha = 0.05, a population proportion of 50%, and a precision of 0.05, and was estimated as at least 384 patients. There are 60 outpatient addiction treatment clinics and 13 NA self-help groups in the inner city of Shiraz which were numbered and then fifteen
outpatient addiction treatment clinics and six NA self-help groups were selected by simple random sampling. Following a screening interview to determine eligibility for the study with more than 1500 patients of selected centers and groups, 552 people were identified as eligible. Data collection was performed by a team including a physician who checked the eligibility of participants. Eligibility was based on patients’ self-report. Participants included two groups: 365 people who have been in sustained remission for the past year, and 187 persons who met SUD criteria and had at least one substance use relapse during the past year. A written informed consent was obtained after the study was explained to all the participants. The study received ethical approval from the local Ethics Committee of Shiraz University of Medical Sciences (code: IR.SUMS.MED.REC.1395.08).

The research instrument was an interviewer-administered structured questionnaire that contained demographic characteristics (age, gender, marital status, educational level, and job) and substance-related questions including age of the onset, primary drug of use, total years of opioid use, history of injection drug use (IDU), opioid use among first degree relatives, number and type of treatment programs (including agonist therapy and participation in self-help groups) and also history of imprisonment. Data were analyzed with the use of SPSS software (version 19, SPSS Inc., Chicago, IL, USA). Comparisons were made by means of independent t-test for continuous variables and chi-square test for categorical variables. For univariate analysis, continuous variables were dichotomized at median values. Subsequently, multivariate logistic regression with backward elimination of variables was performed. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated. Significance level of 0.05 was considered to be statistically significant.

Results

Study participants were opiate users residing in Shiraz City, with at least two years of regular opiate use. The majority of participants were male (87.0%), married (59.6%), had less than 12 years of education (76.8%), employed (65.0%), started opiate use after age of 20 (71.6%), used opiates for more than 5 years (65.9%), and reported opium as their primary drug of use (69.4%). Some participants reported history of IDU (21.2%) and opiate use among first-degree relatives (39.3%). More than one third of participants (37.9%) had tried five times or more episodes of treatment. The most commonly used treatment program was opioid agonist therapy (OAT) (71.9%). There was also a significant proportion of patients (66.5%) who had participated in self-help groups.

Characteristics of study subjects are summarized in table 1. The mean age of those with sustained remission was 42.12 ± 8.48 and of those without it was 41.23 ± 8.02 (P = 0.441).

Those patients who did not achieve sustained remission were more likely to be female patients, with 2-5 years of opioid use and history of imprisonment, and they had commonly used OAT. Those with sustained remission had lower age of onset and positive family support, and had more commonly participated in NA programs.

According to univariate analysis, sustained remission was predicted by male gender (OR: 3.03, CI: 1.83-5.02, P < 0.001), age of onset of opioid use before 20 years (OR: 2.08, CI: 1.36-3.18, P = 0.001), more than 5 years history of opioid use (OR: 2.72, CI: 1.88-3.93, P < 0.001), family support (OR: 3.18, CI: 1.71-5.91, P < 0.001), no history of imprisonment (OR: 1.85, CI: 1.08-3.15, P = 0.032), and participation in self-help groups (OR: 4.23, CI: 2.89-6.18, P < 0.001). It was inversely related to a history of agonist therapy (OR: 0.57, CI: 0.37-0.86, P = 0.007). Sustained remission was not associated with age (P = 0.564), marital status (P = 0.271), education (P = 0.832), job status (P = 0.510), primary drug of use (P = 0.172), history of IDU (P = 0.154), and number of treatment episodes (P = 0.926) (Table 1).

The results of multivariate regression analysis have been shown in table 2. The model explained approximately 26% of the observed variance (pseudo-R^2 = 0.257), and the overall accuracy of the model to predict sustained remission was 66.1%. According to the model, sustained remission was associated with NA participation (AOR = 3.28, 95% CI: 2.19-4.89, P < 0.001), male gender (AOR = 2.53, 95% CI: 1.45-4.43, P = 0.001), younger age of onset (AOR = 1.63, 95% CI: 1.03-2.58, P = 0.037), more total years of opioid use (AOR = 2.13, 95% CI: 1.42-3.19, P < 0.001), no history of imprisonment (AOR = 2.11, 95% CI: 1.16-3.85, P = 0.015), and family support
Narcotic Anonymous Predicts Sustained Remission

Shiraly et al.

Addict Health, Spring 2018; Vol 10, No 2

http://ahj.kmu.ac.ir, 04 April

(AOR = 2.58, 95% CI: 1.33-5.01, P = 0.005). The model showed that being a female and having a history of imprisonment were inversely related to sustained remission (Table 2).

Table 1. Univariate analysis of factors associated with sustained remission among chronic opiate users, Shiraz, Iran

| Variable                                | Total (n = 552) | Not in remission (n = 187) | In sustained remission (n = 365) | OR (95% CI) | P  |
|-----------------------------------------|----------------|---------------------------|---------------------------------|-------------|----|
| Age (year)                              |                |                           |                                 |             |    |
| 20-39                                   | 374 (67.75)    | 130 (69.50)               | 244 (66.80)                     | 1.13 (0.77–1.65) | 0.564 |
| 40-60                                   | 178 (32.25)    | 57 (30.50)                | 121 (33.20)                     |             |    |
| Sex                                     |                |                           |                                 |             |    |
| Male                                    | 480 (86.95)    | 146 (78.10)               | 334 (91.50)                     | 3.03 (1.83–5.02) | < 0.001 |
| Female                                  | 72 (13.05)     | 41 (21.90)                | 31 (8.50)                       |             |    |
| Marital status                          |                |                           |                                 |             |    |
| Married                                 | 329 (59.60)    | 105 (56.10)               | 224 (61.40)                     | 1.24 (0.87–1.77) | 0.271 |
| Single/divorced/widowed                 | 223 (40.40)    | 82 (43.90)                | 141 (38.60)                     |             |    |
| Age of onset of opioid use (year)       |                |                           |                                 |             |    |
| < 20                                    | 157 (28.44)    | 36 (19.30)                | 121 (33.20)                     | 2.08 (1.36–3.18) | 0.001 |
| ≥ 20                                    | 395 (71.56)    | 151 (80.70)               | 244 (66.80)                     |             |    |
| Family support                          |                |                           |                                 |             |    |
| Yes                                     | 83 (15.03)     | 13 (7.00)                 | 70 (19.20)                      | 3.18 (1.71–5.91) | < 0.001 |
| No                                      | 469 (84.97)    | 174 (93.00)               | 295 (80.80)                     |             |    |
| Education (years of schooling)          |                |                           |                                 |             |    |
| ≥ 12                                    | 128 (23.19)    | 42 (22.50)                | 86 (23.60)                      | 1.06 (0.69–1.62) | 0.832 |
| < 12                                    | 424 (76.81)    | 145 (77.50)               | 279 (76.40)                     |             |    |
| Having a job                            |                |                           |                                 |             |    |
| Yes                                     | 359 (65.03)    | 122 (65.20)               | 237 (64.90)                     | 0.97 (0.68–1.43) | 0.510 |
| No                                      | 193 (34.97)    | 65 (34.80)                | 128 (35.10)                     |             |    |
| Primary drug of use                     |                |                           |                                 |             |    |
| Opium                                   | 383 (69.38)    | 137 (73.30)               | 246 (67.40)                     | 1.33 (0.89–1.96) | 0.172 |
| Heroin                                  | 169 (30.62)    | 50 (26.70)                | 119 (32.60)                     |             |    |
| Opioid use in first degree relatives    |                |                           |                                 |             |    |
| Yes                                     | 217 (39.31)    | 63 (33.70)                | 154 (42.20)                     | 0.69 (0.48–1.01) | 0.054 |
| No                                      | 335 (60.69)    | 124 (66.30)               | 211 (57.80)                     |             |    |
| Total years of opioid use               |                |                           |                                 |             |    |
| > 5                                     | 364 (65.94)    | 95 (50.80)                | 269 (73.70)                     | 2.72 (1.88–3.93) | < 0.001 |
| 2-5                                     | 188 (34.06)    | 92 (49.20)                | 96 (26.30)                      |             |    |
| History of IDU                          |                |                           |                                 |             |    |
| Yes                                     | 117 (21.20)    | 33 (17.60)                | 84 (23.00)                      | 0.72 (0.46–1.12) | 0.154 |
| No                                      | 435 (78.80)    | 154 (82.40)               | 281 (77.00)                     |             |    |
| History of imprisonment                 |                |                           |                                 |             |    |
| No                                      | 490 (88.77)    | 158 (84.50)               | 332 (91.00)                     | 1.85 (1.08–3.15) | 0.032 |
| Yes                                     | 62 (11.23)     | 29 (15.90)                | 33 (9.00)                       |             |    |
| NA participation                        |                |                           |                                 |             |    |
| Yes                                     | 367 (66.49)    | 84 (44.90)                | 283 (77.50)                     | 4.23 (2.89–6.18) | < 0.001 |
| No                                      | 185 (33.51)    | 103 (55.10)               | 82 (22.50)                      |             |    |
| History of agonist therapy              |                |                           |                                 |             |    |
| Yes                                     | 397 (71.92)    | 148 (79.10)               | 249 (68.20)                     | 0.57 (0.37–0.86) | 0.007 |
| No                                      | 155 (28.08)    | 39 (20.90)                | 116 (31.80)                     |             |    |
| Treatment episodes                      |                |                           |                                 |             |    |
| 1-4 times                               | 343 (62.14)    | 117 (62.60)               | 226 (61.90)                     | 1.03 (0.71–1.48) | 0.926 |
| ≥ 5 times                               | 209 (37.86)    | 70 (37.40)                | 139 (38.10)                     |             |    |

OR: Odds ratio; CI: Confidence interval; IDU: Injection drug use; NA: Narcotic anonymous
Table 2. Multivariate analysis of factors associated with sustained remission among Iranian chronic opiate addicts, Shiraz, Iran

| Variable                                | B    | SE   | Wald | df | AOR (95% CI)       | P    |
|-----------------------------------------|------|------|------|----|-------------------|------|
| NA participation                        |      |      |      |    |                   |      |
| Yes                                     | 1.188| 0.204| 33.779| 1  | 3.28 (2.19–4.89)   | < 0.001|
| No                                      |      |      |      |    |                   |      |
| History of imprisonment                 |      |      |      |    |                   |      |
| No                                      | 0.746| 0.307| 5.894| 1  | 2.11 (1.16–3.85)   | 0.015 |
| Yes                                     |      |      |      |    |                   |      |
| Primary drug of use                     |      |      |      |    |                   |      |
| Opium                                   | 0.226| 0.228| 0.986| 1  | 1.25 (0.80–1.96)   | 0.321 |
| Heroin                                  |      |      |      |    |                   |      |
| Sex                                     |      |      |      |    |                   |      |
| Male                                    | 0.930| 0.285| 10.655| 1 | 2.53 (1.45–4.43)   | 0.001 |
| Female                                  |      |      |      |    |                   |      |
| Age of onset of opioid use (year)       |      |      |      |    |                   |      |
| < 20                                    | 0.489| 0.235| 4.338| 1  | 1.63 (1.03–2.58)   | 0.037 |
| ≥ 20                                    |      |      |      |    |                   |      |
| Family support                          |      |      |      |    |                   |      |
| Yes                                     | 0.947| 0.339| 7.809| 1  | 2.58 (1.33–5.01)   | 0.005 |
| No                                      |      |      |      |    |                   |      |
| Total years of opioid use               |      |      |      |    |                   |      |
| > 5                                     | 0.756| 0.207|13.338| 1  | 2.13 (1.42–3.19)   | < 0.001|
| 2-5                                     |      |      |      |    |                   |      |
| History of agonist therapy              |      |      |      |    |                   |      |
| Yes                                     |      | 0.233| 1.342| 1  | 0.72 (0.46–1.13)   | 0.155 |
| No                                      | 0.331|      |      |    |                   |      |

AOR: Adjusted odds ratio; CI: Confidence interval; SE: Standard error; df: Degree of freedom; NA: Narcotic anonymous

Discussion

Our findings showed that male opioid addicts were more likely to achieve sustained remission and to stay sober compared to female patients. There was a significant gender difference in prevalence rates, health service use, treatment outcome, and physiological consequences of SUDs. Evidence suggests that female addicts suffer more severe emotional and physical consequences in comparison to men. They usually face numerous barriers including limited access to treatment, stigma, and fear of legal problems. These factors may affect the frequency and duration of remissions.

Another finding of the present study showed that people with earlier age of onset and higher total years of opiate use were more likely to report sustained remission. This finding is in contrast to previous reports which had implied that early age of onset was associated with a higher prevalence of dependency, increased clinical severity, and worsened consequences. However, at the same time, some reports were in line with our findings. For example, in a cohort study on people with different drug addictions, duration of remission was significantly higher in those with age of onset of below 21 years. Moreover, according to this study on heroin addicts, substance cessation attempts 10-20 years after first drug use were more successful. In studies of community and treatment populations, about 60 percent of patients with a SUD eventually achieved sustained recovery at some time in their lives. Whether this is due to experience obtained by repeated cessation attempts or a blunted dopaminergic system is questionable. It has been suggested that chronic drug use might down-regulate dopamine receptors and production in the brain reward system that might help patients to reduce or stop substance use.

Social support from family has been consistently found to predict positive outcomes among drug addicts. The results of our study also supported the association of family support with sustained remission among opioid addicts. It seems that emotional and economic burden and relationship distresses and conflicts can be relieved by a supporting family.

A substantial proportion of people with OUDs experiences imprisonment. A history of...
imprisonment is associated with an ongoing elevated risk of negative outcomes. Almost 75% of prisoners with OUD do not maintain remission 3 months after release from jail.\textsuperscript{30,31} In the present study, lack of history of imprisonment was found to be predictive for sustained remission.

A notable finding of this study was that participation in self-help groups was a significant predictor of sustained remission among chronic opiate users. Some other studies have similarly shown that self-help group participation promoted sustained remission among different drug users.\textsuperscript{30} As an abstinence-based method of addiction treatment, 12-step program helps opioid addicts to stay clean through spiritual practices.\textsuperscript{32} Although this treatment method also follows a multiple stop-and-start pattern,\textsuperscript{10} the present study showed that those with a history of participation in self-help groups were more likely to stay in sustained remission. In some treatment programs, NA meetings are used as a complementary treatment, which has shown to enhance maintenance of the relapse-free state.\textsuperscript{33} It seems that participation in 12-step programs promotes positive psycho-emotional changes that help opioid addicts to stay in remission for longer periods of time.

The present findings suggest that OAT, despite its considerable benefits, is not significantly associated with sustained remission. Maintenance treatment with methadone reduces injecting practice, crime, risk of blood borne viral infections, and drug overdose, and improves social function.\textsuperscript{34-36} At the same time, relapses are common with this modality, and according to a prospective study, just 27% of opiate addicts under methadone therapy had 4 months or longer periods of remission.\textsuperscript{10} As a substitute method, agonist therapy is an appropriate tool for controlling opioid addiction as far as the substitute drug is used, but it does not seem to significantly affect the rate of sustained remission.

Most chronic addicts, who achieve sustained recovery, do so after at least one episode of formal treatment.\textsuperscript{27} Our findings showed that there was no association between the number of previous treatment episodes and the experience of sustained remission. A longitudinal study on 1326 patients for 9 years showed a negative association between number of treatment episodes and sustained remission. In the aforementioned study, after the initial 6 months of treatment, the likelihood of sustained remission decreased as the number of subsequent treatment episodes increased.\textsuperscript{15} Maybe the quality and type of treatments and use of complementary methods like 12-step programs, as our findings showed, are more important determinants of sustained remission.

There are some limitations to our study. First, this was a cross-sectional study based on participants’ self-report. The validity of self-reported data cannot be established and the collected information is subject to bias. Second, we did not assess factors such as mental distress and duration of retention in treatments. Third, we considered drug addicts who were seeking treatments; therefore, the enrolled population might not be representing all chronic opiate addicts.

**Conclusion**

According to our findings, participation in self-help groups can be a suitable alternative in predicting sustained remission among chronic opiate users. Moreover, male chronic opiate addicts with earlier age of onset of drug use and longer history of opioid use are more likely to report sustained remission. Chronic opioid users should be encouraged by the physicians who are involved in the treatment of drug addiction to participate in NA programs.

**Conflict of Interests**

The Authors have no conflict of interest.

**Acknowledgements**

We gratefully acknowledge the support given to our effort by the Vice Chancellor for Research and Technology of Shiraz University of Medical Sciences. The authors wish to thank Mr. H. Argasi at the Research Consultation Center of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript.

**References**

1. Naji L, Dennis BB, Bawor M, Varenbut M, Daiter J, Plater C, et al. The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone
maintenance therapy. Addict Sci Clin Pract 2017; 12(1): 9.

2. Bart G. Maintenance medication for opiate addiction: The foundation of recovery. J Addict Dis 2012; 31(3): 207-25.

3. Kosten TR, George TP. The neurobiology of opioid dependence: Implications for treatment. Sci Pract Perspect 2002; 1(1): 13-20.

4. Shekarchizadeh H, Ekhtiari H, Khami MR, Virtanen JI. Patterns of pre-treatment drug abuse, drug treatment history and characteristics of addicts in methadone maintenance treatment in Iran. Harm Reduct J 2012; 9: 18.

5. Amin-Esmaili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtahab R, et al. Epidemiology of illicit drug use disorders in Iran: Prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction 2016; 111(10): 1836-47.

6. Montazi S, Rawson R. Substance abuse among Iranian high school students. Curr Opin Psychiatry 2010; 23(3): 221-6.

7. Kassani A, Niazi M, Hassanzadeh J, Menati R. Survival analysis of drug abuse relapse in addiction treatment centers. Int J High Risk Behav Addict 2015; 4(3): e23402.

8. Fuchs RA, Lasseret HC, Ramirez DR, Xie X. Relapse to drug seeking following prolonged abstinence: The role of environmental stimuli. Drug Discov Today Dis Models 2008; 5(4): 251-8.

9. Laudet AB, Savage R, Mahmood D. Pathways to long-term recovery: A preliminary investigation. J Psychoactive Drugs 2002; 34(3): 305-11.

10. Krentzman AR, Robinson EA, Moore BC, Kelly JF, Laudet AB, White WL, et al. How alcoholics anonymous (AA) and narcotics anonymous (NA) work: Cross-disciplinary perspectives. Alcohol Treat Q 2010; 29(1): 75-84.

11. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: Options in pharmacotherapy. Expert Opin Pharmacother 2009; 10(11): 1727-40.

12. Gyarmathy VA, Latkin CA. Individual and social factors associated with participation in treatment programs for drug users. Subst Use Misuse 2008; 43(12-13): 1865-81.

13. Reichel CM, Bevins RA. Forced abstinence model of relapse to study pharmacological treatments of substance use disorder. Curr Drug Abuse Rev 2009; 2(2): 184-94.

14. Satel S, Lilienfeld SO. Addiction and the brain-disease fallacy. Front Psychiatry 2013; 4: 141.

15. Scott CK, Dennis ML, Laudet A, Funk RR, Simeone RS. Surviving drug addiction: the effect of treatment and abstinence on mortality. Am J Public Health 2011; 101(4): 737-44.

16. Nosyk B, Anglin MD, Brecht ML, Lima VD, Hser YI. Characterizing durations of heroin abstinence in the California civil addict program: Results from a 33-year observational cohort study. Am J Epidemiol 2013; 177(7): 675-82.

17. McCabe SE, Cranford JA, Boyd CJ. Stressful events and other predictors of remission from drug dependence in the United States: Longitudinal results from a national survey. J Subst Abuse Treat 2016; 71: 41-7.

18. Charney DA, Palacios-Boix J, Negrete JC, Dobkin PL, Gill KJ. Association between concurrent depression and anxiety and six-month outcome of addiction treatment. Psychiatr Serv 2005; 56(8): 927-33.

19. Mertens JR, Kline-Simon AH, Delucchi KL, Moore C, Weissner CM. Ten-year stability of remission in private alcohol and drug outpatient treatment: Non-problem users versus abstainers. Drug Alcohol Depend 2012; 125(1-2): 67-74.

20. Compton WM, Dawson DA, Conway KP, Brodsky M, Grant BF. Transitions in illicit drug use status over 3 years: A prospective analysis of a general population sample. Am J Psychiatry 2013; 170(6): 660-70.

21. McKay JR, Van Horn D, Rennert L, Drapkin M, Ivey M, Koppenhaver J. Factors in sustained recovery from cocaine dependence. J Subst Abuse Treat 2013; 45(2): 163-72.

22. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am J Psychiatry 2013; 170(8): 834-51.

23. Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, et al. Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 2011; 37(5): 313-23.

24. Saia KA, Schiff D, Wachman EM, Mehta P, Vilkins A, Sia M, et al. Caring for pregnant women with opioid use disorder in the USA: Expanding and improving treatment. Curr Obstet Gynecol Rep 2016; 5: 257-63.

25. Sharma B, Bruner A, Barnett G, Fishman M. Opioid use disorders. Child Adolesc Psychiatr Clin N Am 2016; 25(3): 473-87.

26. Odgers CL, Caspi A, Nagin DS, Piquero AR, Slutske WS, Milne BJ, et al. Is it important to prevent early exposure to drugs and alcohol among adolescents? Psychol Sci 2008; 19(10): 1037-44.

27. Dennis M, Scott CK. Managing addiction as a chronic condition. Addict Sci Clin Pract 2007; 4(1): 45-55.

28. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F, Baler R. Addiction: Decreased reward
sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuit. Bioessays 2010; 32(9): 748-55.

29. Kelly SM, O'Grady KE, Schwartz RP, Peterson JA, Wilson ME, Brown BS. The relationship of social support to treatment entry and engagement: The community assessment inventory. Subst Abus 2010; 31(1): 43-52.

30. Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: A qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract 2015; 10: 2.

31. Larney S, Cama E, Nelson E, Larance B, Degenhardt L. A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia. Drug Alcohol Rev 2016; 35(6): 686-92.

32. Sussman S. A review of alcoholics anonymous/narcotics anonymous programs for teens. Eval Health Prof 2010; 33(1): 26-55.

33. Vederhus JK, Kristensen O. High effectiveness of self-help programs after drug addiction therapy. BMC Psychiatry 2006; 6: 35.

34. Remski K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract 2012; 3(1): 45-50.

35. Teoh Bing Fei J, Yee A, Habil MH, Danaee M. Effectiveness of methadone maintenance therapy and improvement in quality of life following a decade of implementation. J Subst Abuse Treat 2016; 69: 50-6.

36. Garcia-Portilla MP, Bobes-Bascaran MT, Bascaran MT, Saiz PA, Bobes J. Long term outcomes of pharmacological treatments for opioid dependence: Does methadone still lead the pack? Br J Clin Pharmacol 2014; 77(2): 272-84.
بررسی عوامل مرتبط با بهبود پاییدار در مصرف کننده‌گان مزمن مواد ایپیوئیدی

دکتر رامین شیرالی‌آرا، دکتر مريم تقوا

چکیده

مقدمه: مصرف مزمن مواد ایپیوئیدی، مشکل عمده سلامت جامعه است که با عوارض قابل توجهی همراه می‌باشد. پژوهش‌های حاضر با هدف بررسی عوامل مرتبط با بهبود پاییدار در مصرف کننده‌گان مواد ایپیوئیدی، شهر شیراز انجام شد.

روش‌ها: این مطالعه از نوع مقطعی بود که جهت ارزیابی بهبود پاییدار در مصرف کننده‌گان در شهر شیراز انجام گردید. شرکت کننده‌گان شامل دو گروه بود: 1) ۳۸۵ نفر که مدتی در سال گذشته در بهبودی بوده، 2) ۱۸۷ نفر که مدتی بهبودی به دست نیاورده بودند. تعداد ۳۶۵ نفر از گروه ۱ و ۱۸۷ نفر از گروه ۲، بانک آمار ایران را به دست آورد. تعداد ۱۸۷ نفر از گروه ۲، مصرف مواد اپیوئیدی را بهبودی می‌دانستند. جهت انجام تحقیق، مدت مورد نظر، پیش‌بینی، مصرف مواد اپیوئیدی و جهت برآورد نسبت شانس سازگار شده نیز روش Pearson χ² از روش‌های آزمون χ² استفاده گردید.

Yates‌ها: بهبود پاییدار با شرکت در جلسات متقابل بین خانواده ۰/۶۵ (CI Confidence interval = 0/4/88, P = 0/002 < OR), جنس مذکر (۱) (OR), سن کمتر شروع مصرف (OR = 0/4/88, CI = 0/3/0, P = 0/001 < OR) و نسبت بین مصرف (CI = 0/9/46, P = 0/001 < OR) داشتند. در شرکت در برنامه‌های توانمندسازی، شکافه‌های نسبت به بهبود پاییدار و بهبود در برنامه‌های توانمندسازی و شکافه‌های نسبت به مصرف مواد اپیوئیدی باشد. 

نتیجه‌گیری: شرکت در برنامه‌های توانمندسازی مناسبی برای پیش‌بینی بهبود پاییدار در مصرف کننده‌گان مزمن مواد ایپیوئیدی باشد. 

واژگان کلیدی: اعتیاد به دارو، ایپیوئید، اختلالات سوء مصرف مواد، درمان گروه‌گیری ایپیوئید

ارجاع: شیرالی، رامین، تقویت می‌نماید. بررسی عوامل مرتبط با بهبود پاییدار در مصرف کننده‌گان مزمن مواد ایپیوئیدی. مجله اعتیاد و سلامت ۱۳۹۷: ۱۳۹۶-۳۹.

تاریخ دریافت: ۹۶/۱۲/۱۹

لیست مراجع:
1- استادیار، گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی شیراز، شیراز، ایران
2- دانشیار، گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی شیراز، شیراز، ایران
3- لیسته مسئول: دکتر رامین شیرالی

Email: shiralyr@sums.ac.ir

Addict Health, Spring 2018; Vol 10, No 2

http://ahj.kmu.ac.ir, 04 April